Last reviewed · How we verify
Amino acid solution
Amino acid solution provides essential and non-essential amino acids for protein synthesis and metabolic support in patients unable to obtain adequate nutrition orally.
Amino acid solution provides essential and non-essential amino acids for protein synthesis and metabolic support in patients unable to obtain adequate nutrition orally. Used for Parenteral nutrition support in patients unable to receive adequate oral or enteral nutrition, Post-operative nutritional support, Critical illness and severe malnutrition.
At a glance
| Generic name | Amino acid solution |
|---|---|
| Also known as | Alamin SN ®, Albert D Limited, Kolkata, India, Parenteral nutrition, l arginine |
| Sponsor | B.P. Koirala Institute of Health Sciences |
| Drug class | Parenteral nutrition supplement |
| Modality | Small molecule |
| Therapeutic area | Nutrition support / Critical care |
| Phase | FDA-approved |
Mechanism of action
Amino acid solutions are parenteral nutrition formulations that deliver a balanced mixture of amino acids intravenously to support protein metabolism, wound healing, and immune function. They are used in clinical settings where oral or enteral nutrition is not feasible, such as post-operative recovery, critical illness, or severe malnutrition. The specific amino acid composition may be tailored to support hepatic, renal, or metabolic conditions.
Approved indications
- Parenteral nutrition support in patients unable to receive adequate oral or enteral nutrition
- Post-operative nutritional support
- Critical illness and severe malnutrition
Common side effects
- Phlebitis at infusion site
- Hyperglycemia
- Electrolyte imbalances
- Hepatic dysfunction with prolonged use
Key clinical trials
- Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) (PHASE2, PHASE3)
- Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer (PHASE3)
- Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer (PHASE2)
- A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis (PHASE3)
- A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (PHASE3)
- 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer (PHASE1, PHASE2)
- Induced Suppression of Platelet Activity in Aneurysmal Subarachnoid Hemorrhage Management-2 (iSPASM-2) (PHASE1, PHASE2)
- EUSOL vs. PDGF Dressing for Diabetic Foot Ulcers (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amino acid solution CI brief — competitive landscape report
- Amino acid solution updates RSS · CI watch RSS
- B.P. Koirala Institute of Health Sciences portfolio CI